报价延迟最少15分钟:2026/07/18 23:15 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.93 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.30/--
|
|
企业价值
4.48B
|
| 资产负债 |
|
每股账面净值
12.86
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
3.10B
|
|
每股收益
0.45
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI)Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World. |
